IPIROC: INTERMITTENT PARP INHIBITOR REGIMEN IN OVARIAN CANCER
PARP inhibitors (PARPi) have revolutionized the treatment of ovarian and other cancers with mutations in the BRCA genes and homologous recombination deficiency (HRD). However, majority of women globally cannot afford the cost of the recommended daily dosing of PARPi, leading to financial burden and health disparity. Hematological or blood cell-related toxicities associated with daily dosing of PARPi, especially in women with lower body weight or pre-existing anemia, pose a significant challenge. Laboratory studies have shown that a single dose of the PARPi rucaparib can inhibit PARP beyond 72 hours, providing a proof-of-concept for optimal scheduling with a less frequent dosing regimen. Our pilot trial (CRUK-DBT funded) confirms that intermittent bi-weekly (2 days a week) scheduling can significantly reduce the side effects and the cost of treatment (1/4th). Some women have attained long-term disease-free period with this well-tolerated regimen; however, larger clinical trials are needed to generate further evidence on optimized dosing schedules rather than using empirical dose reduction practices without any pre-clinical scientific data. This is the goal for our IPIROC Umbrella studies (KolGO-PROVAR 002).
TO REGISTER YOUR INTEREST FOR PARTICIPATION, PLEASE CLICK HERE
FOR MORE DETAILS OR TO EXPRESSS INTEREST IN PARTICIPATION, PLEASE CONTACT US AT research@kolgotrg.org
Intermittent PARP Inhibitor Regimen in Ovarian Cancer (IPIROC). Click here..
IPIROC leaflet for researchers version 1.1. Click here..